Calumet 公司
估值 各估值倍数与自身5年区间的对比
同业对比 Specialty Chemicals
| 公司 | 市值 | 市盈率(TTM)i | 市净率i | 股息率i |
|---|---|---|---|---|
| Calumet 公司 (CLMT) | 5.08B | -37.50 | -4.46 | 0.00% |
| Linde (LIN) | 229.77B | 32.16 | 5.88 | 1.24% |
| Sherwin-Williams (SHW) | 81.37B | 30.92 | 21.11 | 0.95% |
| Ecolab (ECL) | 80.98B | 38.78 | 8.05 | 0.98% |
| Air Products & Chemicals (APD) | 66.71B | -1,426.62 | 4.81 | 2.40% |
| PPG Industries (PPG) | 23.87B | 15.36 | 2.83 | 2.64% |
StockVane 追踪范围内同行业的其他公司。
Morningstar
当前股价高于晨星合理价值估算32.3%。
合理价值
Calumet Inc is assigned a 2-star quantitative star rating, indicating our belief that this share class is a somewhat unattractive choice, and investors should look elsewhere for more fruitful opportunities. The stock currently trades at a 43% premium over our quantitative fair value estimate of $39.09 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating.
The firm's valuation metrics weaken our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its enterprise value to EBITDA ratio of 342.4, which ranks in the top 10% compared with peers globally. This suggests that the value of its enterprise value, or the value of its shares and debt, is a high multiple of the generated EBITDA. We believe this is a sign that shares could be overvalued.
The company's lack of profitability is an additional cause for concern. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's gross margin of -2.8%, for example, lies in the bottom 10% globally. This suggests that competition is intense and profit generation could prove difficult. This characteristic further promotes our unfavorable price/fair value ratio.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.
经济护城河
This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.
作者:Quantitative Equity Report
报价时间 2026-10-16 20:02:13 · 仅供参考,不构成投资建议,也未考虑您的具体情况。
Calumet 公司 讨论区 0 条评论